With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions. Also find how you can save time and get recognition for commercial insight.
Biosimilar mAbs - assess their potentials now, seeing what you can gain
Our study shows you data, trends, opportunities, and sales predictions for biosimilar mAbs. Avoid missing out - please order our new report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Table of Contents 1. Executive Summary 1.1 What This Report Covers
1.2 Biosimilar MAbs: World Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods
2. Introduction to Biosimilar Monoclonal Antibodies
2.1 Natural Antibodies: Key to the Immune System2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)2.3 Humanising the MAb2.4 Biologics and Biosimilars2.5 Why are Biosimilars in Demand?2.6 Considerations for the Development of Biosimilars2.6.1 Biologics and Biosimilars Are Large, Complex Molecules2.6.2 How Big a Concern Is Immunogenicity?2.7 Biosimilar Monoclonal Antibodies Already on the Market
3. World Market Prospects for Biosimilar Monoclonal Antibodies, 2013-2023
3.1 The World Market for Biosimilar Monoclonal Antibodies in 2012: 3 Biosimilar MAbs on the Market
3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2013-2023
3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2018 and 2023
3.4 The World Market for Biosimilar MAbs by Compound: Grouped Revenue Forecast, 2013-2023
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Inflixim
Copyright©2012 PR Newswire.
All rights reserved